Literature DB >> 2572436

Beta-adrenoceptors in human brain labelled with [3H]dihydroalprenolol and [3H]CGP 12177.

F De Paermentier1, S C Cheetham, M R Crompton, R W Horton.   

Abstract

beta-Adrenoceptor binding sites were characterised and quantitated in post-mortem human brain with [3H]dihydroalprenolol ([3H]DHA) and [3H]CGP 12177. In cerebral cortex, isoprenaline and propranolol displaced both radioligands with uniform affinity. Practolol and CGP 20712A (selective beta 1-adrenoceptor antagonists) displaced with high affinity from a greater proportion of sites than ICI 118,551 and IPS 339 (selective beta 2-adrenoceptor antagonists). In cerebellum, propranolol displaced both radioligands with uniform affinity. ICI 118,551 displaced with high affinity from a greater proportion of sites than CGP 20712A. The density of total beta-adrenoceptors (defined with isoprenaline) and of beta 1- and beta 2-adrenoceptors (defined with CGP 20712A and ICI 118,551 respectively) was studied by saturation binding of both radioligands in 13 brain areas. beta-Adrenoceptor density was higher in caudate, putamen and nucleus accumbens (100-120 fmol/mg protein) than cortex (50-70 fmol/mg protein) and densities were lowest in hypothalamus and cerebellum (27-38 fmol/mg protein). The proportion of beta 1-adrenoceptors (as a % of total beta-adrenoceptors) was high in caudate (80%), putamen (80%) and cortex (60-70%) and lower in hippocampus (40%) and cerebellum (30%). Both radioligands labelled a very similar number of beta-adrenoceptors in all brain regions studied.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2572436     DOI: 10.1016/0014-2999(89)90448-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Brain beta-adrenoceptor binding sites in depressed suicide victims: effects of antidepressant treatment.

Authors:  F De Paermentier; S C Cheetham; M R Crompton; C L Katona; R W Horton
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

2.  Demonstration of the suitability of CGP 12177 for in vivo studies of beta-adrenoceptors.

Authors:  M P Law
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

3.  Beta-adrenoceptor density and subtype distribution in cerebellum and hippocampus from patients with Alzheimer's disease.

Authors:  B Lemmer; L Langer; T Ohm; J Bohl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-02       Impact factor: 3.000

Review 4.  The dopamine hypothesis of schizophrenia: limbic interactions with serotonin and norepinephrine.

Authors:  J N Joyce
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Desipramine administration in the olfactory bulbectomized rat: changes in brain beta-adrenoceptor and 5-HT2A binding sites and their relationship to behaviour.

Authors:  N T Mudunkotuwa; R W Horton
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

6.  Repeated administration of desipramine and a GABAB receptor antagonist, CGP 36742, discretely up-regulates GABAB receptor binding sites in rat frontal cortex.

Authors:  G D Pratt; N G Bowery
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.